Menu Search
Equities

China Resources Pharmaceutical Group Ltd

640:STU

China Resources Pharmaceutical Group Ltd

Actions
  • Price (EUR)0.55
  • Today's Change0.005 / 0.92%
  • Shares traded0.00
  • 1 Year change-7.56%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year China Resources Pharmaceutical Group Ltd grew revenues 12.16% from 218.18bn to 244.70bn while net income improved 10.11% from 3.50bn to 3.85bn.
Gross margin15.78%
Net profit margin3.31%
Operating margin4.65%
Return on assets3.19%
Return on equity7.95%
Return on investment12.13%
More ▼

Cash flow in CNYView more

In 2023, China Resources Pharmaceutical Group Ltd increased its cash reserves by 61.92%, or 9.43bn. The company earned 15.55bn from its operations for a Cash Flow Margin of 6.35%. In addition the company used 2.07bn on investing activities and also paid 4.07bn in financing cash flows.
Cash flow per share2.02
Price/Cash flow per share2.40
Book value per share8.46
Tangible book value per share3.33
More ▼

Balance sheet in CNYView more

China Resources Pharmaceutical Group Ltd has a Debt to Total Capital ratio of 43.96%, a higher figure than the previous year's 26.61%.
Current ratio1.37
Quick ratio1.12
Total debt/total equity1.57
Total debt/total capital0.4396
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)2.97%
Div growth rate (5 year)7.05%
Payout ratio (TTM)25.64%
EPS growth(5 years)2.81
EPS (TTM) vs
TTM 1 year ago		2.57
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.